{"favorite_id": 3647, "calc_type": "", "dosing": false, "full_title_en": "Gail Model for Breast Cancer Risk", "short_title_en": "Gail Model for Breast CA Risk", "medium_description_en": "Estimates risk for breast cancer based on demographic and clinical data.", "short_description_en": "Breast CA risk based on demographic and clinical data.", "before_use": "<p>This calculator includes inputs based on race, which may or may not provide better estimates; this calculator can be run with Race as &ldquo;Unknown,&rdquo; but users should know this defaults to the &ldquo;White&rdquo; option. Our evidence section reviews some of the issues with Race in this model.&nbsp;<a href=\"https://www.mdcalc.com/race\" rel=\"noopener noreferrer\" target=\"_blank\" data-saferedirecturl=\"https://www.google.com/url?q=https://www.mdcalc.com/race&amp;source=gmail&amp;ust=1632945061987000&amp;usg=AFQjCNFHRRxG7_ZvVdEhZIQz2LsJKodMKw\">See here</a> for more on our approach to addressing race and bias on MDCalc.</p>", "instructions_en": "<p>The Gail Model is for use in women with no history of breast cancer, DCIS or LCIS. Other tools may be more appropriate for women with known mutations in BRCA1, BRCA2, or other hereditary syndromes associated with breast cancer. See the Evidence section for more information.</p>", "purpose_en": ["Prognosis"], "disease_en": ["Breast Cancer"], "specialty_en": ["Family Practice", "Hematology and Oncology", "Internal Medicine", "OB-Gyn", "Radiation Oncology", "Radiology", "Surgery (General)"], "chief_complaint_en": ["Weight Loss/Gain"], "system_en": ["Oncologic"], "search_abbreviation_en": ["Gail", "ca", "breast", "brca1"], "slug": "gail-model-breast-cancer-risk", "seo": {"meta_description_en": "The Gail Model for Breast Cancer Risk estimates risk for breast cancer based on demographic and clinical data.", "keywords_en": "Gail Model for Breast Cancer Risk, gail model, gail calculator, gail model for breast ca, breast cancer awareness, breast cancer prognosis, brCA prognostic tool, risk of breast cancer, risk calculator breast cancer"}, "content": {"how_to_use": {"use_case_en": "<p>The Gail Model is one of several risk assessment models that can help determine the absolute 5 year risk and lifetime risk of developing breast cancer.</p> <ul> <li>Other models include the Tyrer-Cuzick (also referred to as IBIS, International Breast Cancer Intervention Study) model, the Claus model, BRCAPro, and BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm).</li> </ul>", "pearls_pitfalls_en": "<ul> <li>The Gail Model for Breast Cancer risk estimates the absolute 5 year risk and lifetime risk of developing breast cancer.</li> <li>Family history includes only first degree relatives with breast cancer, which is not enough information to estimate the risk of a patient having BRCA mutation. It also underestimates the cancer risk for patients with extensive family history.</li> <li>The Gail Model is a good predictor of risk for populations but not for individuals.</li> <li>It adjusts risk for race/ethnicity.</li> <li>It may underestimate breast cancer risk in patients with atypical hyperplasia and strong family history.</li> <li>The Gail Model was NOT designed to estimate risk for: <ul> <li>Women with a prior diagnosis of breast cancer, lobular carcinoma in situ (LCIS), or ductal carcinoma in situ (DCIS).</li> <li>Women who have received previous radiation therapy to the chest for treatment of Hodgkin lymphoma.</li> <li>Women with gene mutations in BRCA1 or BRCA2, or those who are known to have certain genetic syndromes that increase risk for breast cancer.</li> <li>Women of age &lt;35 or &gt;85.</li> </ul> </li> </ul>", "why_use_en": "<p>It helps determine which risk-reduction options\u2014medical (chemoprevention with tamoxifen), surgical (prophylactic mastectomy) or lifestyle changes only\u2014are most appropriate for individual patients by weighing risks and benefits of intervention versus likelihood of developing cancer.</p> "}, "next_steps": {"advice_en": "<p>Patients who have an increased risk of developing breast cancer, defined as calculated 5 year risk >1.7%, are candidates for chemoprevention (such as tamoxifen).</p>", "management_en": "", "critical_actions_en": "<p>Patients with elevated breast cancer risk (>1.7%) should be referred to a breast surgeon to discuss possible risk reduction interventions.</p> "}, "about": {"formula_en": "", "more_info_en": "<ul> <li>The Gail Model is one of the oldest risk models\u2014originally published in 1989\u2014and well validated.</li> <li>These parameters were used as criteria for the National Surgical Adjuvant Breast and Bowel Project (NSABP) prevention trials to identify patients with increased risk of breast cancer (5 year risk of &gt;1.7%).</li> <li>Lifetime risk estimates assume a life expectancy of 90 years.</li> </ul>", "evidence_based_medicine_en": "<ul> <li>The <a href='http://www.ncbi.nlm.nih.gov/pubmed/2593165?dopt=Abstract' target='_blank'>original Gail model</a> (also known as Gail model 1) was developed in 1989 using data derived from a subset of the Breast Cancer Detection Demonstration Project, a breast cancer screening program that ran from 1973 to 1980, and was initially designed to predict the risk of developing invasive cancer or carcinoma in situ.</li> <li>The Gail model was modified by statisticians (also known as Gail model 2) in order to predict the risk of invasive cancer specifically, and the modified version is the basis for the model that is widely used today.</li> <li>Both models were <a href='http://www.ncbi.nlm.nih.gov/pubmed/10491430?dopt=Abstract' target='_blank'>validated</a> in 1999 for the National Surgical Adjuvant Breast and Bowel Project (NSABP) using data from the Breast Cancer Prevention Trial, based on data from 5,969 white women age 35 and older.</li> <li>Gail and colleagues carried out a <a href='https://www.ncbi.nlm.nih.gov/pubmed/18042936' target='_blank'>case-control study</a> in 2007 looking specifically at risk for black women, and found that the original model underestimated the risk in this population. They developed a model based on data from 1,607 black women with invasive breast cancer and 1,647 without in the Women's Contraceptive and Reproductive Experiences (CARE) Study and found that 30.3% of black women had elevated risk (using a cutoff of 1.66% for 5-year risk), compared with 14.5% as estimated by the previous tool. The Gail model now incorporates these findings to estimate risk for black women.</li> <li>Similarly, they developed a <a href='https://www.ncbi.nlm.nih.gov/pubmed/21562243' target='_blank' data-saferedirecturl='https://www.google.com/url?hl=en&amp;q=https://www.ncbi.nlm.nih.gov/pubmed/21562243>model</a> specific for Asian and Pacific Islander American women, looking at 589 cases and 952 controls in the Asian American Breast Cancer Study, and calibrated their model using data from the Women's Health Initiative (WHI). They found that the previous Gail model tended to <i>over</i>estimate risk in this population. The Gail model now incorporates these findings to estimate risk for Asian and Pacific Islander American women.</li> <li>With regard to newer models, <a href='http://www.ncbi.nlm.nih.gov/pubmed/14627668' target='_blank'>Amir and colleagues</a> compared four different breast cancer risk assessment models in 1,933 patients and found that the Tyrer-Cuzick model was superior (the Gail model, Claus model, and BRCAPRO all underestimated risk).</li> </ul>", "references_list": {"Original/Primary Reference": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/2593165?dopt=Abstract", "text": "Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Shairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879-86, 1989"}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/10547390", "text": "Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91(21):1829-46, 1999."}, {"href": "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11238697&query_hl=7&itool=pubmed_docsum", "text": "Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA: Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93(5):358-66, 2001."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/18042936", "text": "Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, and Bernstein L. Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women. J Natl Cancer Inst 99(23):1782-1792, 2007."}, {"href": "http://www.ncbi.nlm.nih.gov/pubmed/21562243", "text": "Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, Gail MH. Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Island American Women. J Natl Cancer Inst 2011."}, {"href": "http://www.ncbi.nlm.nih.gov/pubmed/14627668 ", "text": "Amir E, Evans DG, Shenton A et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003;40:807-814"}, {"href": "http://www.ncbi.nlm.nih.gov/pubmed/23127309", "text": "Quante AS, Whittemore AS, Shriver T et al. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res. 2012 Nov 5;14(6):R144"}, {"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827770/", "text": "Banegas MP, Gail MH, LaCroix A, Thompson B, Martinez ME, Wactawski-Wende J, John EM, Hubbell FA, Yasmeen S, Katki HA. Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat. 2012 Feb;132(1):347-53."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/14983484", "text": "Kaur JS, Roubidoux MA, Sloan J, Novotny P. Can the Gail model be useful in American Indian and Alaska Native populations? Cancer. 2004 Mar 1;100(5):906-12"}], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/10491430?dopt=Abstract", "text": "Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541-8, 1999."}], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "", "firstName": "Akiko", "img": "", "lastName": "Chiba", "name": "Akiko Chiba, MD", "target": "", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"id": 363, "name": "Dr. Mitchell Gail", "qa_en": "", "approved": false, "priority": 0, "creator_info": {"about_en": "<p>Mitchell Gail, MD, PhD, is an adjunct professor at Johns Hopkins University and a principal investigator at the National Cancer Institute Division of Cancer Epidemiology & Genetics, Biostatistics Branch. He is a former president of the American Statistical Association. He has won numerous awards, most notably the American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention. His research focuses on creating models for determining absolute risk of diseases.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-mitchell-gail.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Gail+MH%5BAuthor%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"label_en": "Age", "conditionality": "", "default": null, "tips_en": "Valid for women 35-85 years old.", "optional": false, "name": "userCurrentAge", "unit": "gail_age", "type": "textbox", "unit_info": {"name": "Age", "conversion": 1, "error_min": 34, "error_max": 85, "warn_min": 35, "warn_max": 84, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "years", "units_us": "years"}}, {"type": "radio", "label_en": "First menstrual period", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "Unknown", "value": 0}, {"label": "7-11 years old", "value": 1}, {"label": "12-13 years old ", "value": 2}, {"label": ">13 years old", "value": 3}], "name": "userMenarcheAge"}, {"type": "radio", "label_en": "First live birth", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "Unknown", "value": 5}, {"label": "No births", "value": 0}, {"label": "<20 years old", "value": 1}, {"label": "20-24 years old", "value": 2}, {"label": "25-29 years old", "value": 3}, {"label": "\u226530 years old", "value": 4}], "name": "userFirstLiveBirthAge"}, {"type": "radio", "label_en": "First-degree relatives with breast cancer", "default": null, "conditionality": "", "show_points": false, "tips_en": "Include only mother, sisters and daughters", "optional": false, "options": [{"label": "Unknown", "value": 0}, {"label": "0", "value": 1}, {"label": "1", "value": 2}, {"label": ">1", "value": 3}], "name": "userFirstDegreeRel"}, {"type": "radio", "label_en": "Previous breast biopsy", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "Unknown", "value": 0}, {"label": "0", "value": 1}, {"label": "1", "value": 2}, {"label": ">1", "value": 3}], "name": "userHadBiopsy"}, {"type": "radio", "label_en": "\u22651 breast biopsy with atypical hyperplasia", "default": null, "conditionality": "userHadBiopsy == 2 || userHadBiopsy == 3", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "Unknown", "value": 0}, {"label": "No", "value": 1}, {"label": "Yes", "value": 2}], "name": "userHyperPlasia"}, {"type": "radio", "label_en": "Race/ethnicity", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "White", "value": 0}, {"label": "African-American", "value": 1}, {"label": "Hispanic", "value": 2}, {"label": "Asian-American", "value": 3}, {"label": "American-Indian/Alaskan Native", "value": 9}, {"label": "Unknown", "value": 10}], "name": "userRace"}, {"type": "radio", "label_en": "Asian-American sub race", "default": null, "conditionality": "userRace == 3", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "Chinese", "value": 3}, {"label": "Japanese", "value": 4}, {"label": "Filipino", "value": 5}, {"label": "Hawaiian", "value": 6}, {"label": "Pacific Islander", "value": 7}], "name": "asianSubRace"}], "md5": "", "cmeVersion": null, "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 10101, "short_title_en": "TNM Breast CA Staging (8th Ed.)", "slug": "tnm-staging-breast-cancer-8th-edition"}, {"calcId": 2170, "short_title_en": "TNM Breast CA Staging", "slug": "tnm-staging-breast-cancer"}, {"calcId": 2048, "short_title_en": "Gleason Score", "slug": "gleason-score-prostate-cancer"}]}